首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1701447

血漿分餾市場規模、佔有率、成長分析（按產品、應用、最終用戶、地區）- 2025 年至 2032 年產業預測

Plasma Fractionation Market Size, Share, and Growth Analysis, By Product (Immunoglobulins, Coagulation Factor Concentrates), By Application (Neurology, Immunology), By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年04月01日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球血漿分餾市場規模價值為 334.3 億美元，預計將從 2024 年的 362 億美元成長到 2032 年的 685.2 億美元，預測期內（2025-2032 年）的複合年成長率為 8.3%。

全球血漿分餾市場預計將經歷顯著成長，主要原因是人口老化，導致人們越來越容易患上需要血漿療法治療的罕見疾病。血漿分餾涉及分離血漿以生產重要產品，例如免疫球蛋白和第八因子，這些產品對於治療血友病和免疫力缺乏等疾病至關重要。這些治療應用的日益普及以及血漿採集設施的激增進一步推動了市場擴張。此外，政府為提高人們對血漿衍生產品的認知而採取的措施也促進了市場的動態。然而，這些血漿衍生物的高成本帶來了越來越大的挑戰，凸顯了製定策略來提高醫療保健環境中的可負擔性和可近性的必要性。

市場概覽
免疫球蛋白
- 靜脈注射免疫球蛋白
- 皮下注射免疫球蛋白
- 其他免疫球蛋白
凝血因子濃縮物
- 第八因子
- 凝血因子IX
- 血管性血友病因子
- 凝血酶原複合物濃縮物
- 纖維蛋白原濃縮物
- 因子 XIII
- 其他凝血因子濃縮物
白蛋白
蛋白酶抑制劑
其他血漿產品

血漿分餾市場規模（依應用）及複合年成長率（2025-2032）

市場概覽
神經病學
免疫學
血液學
加護治療
呼吸系統醫療設備
血液學/腫瘤學
風濕病學
其他用途

血漿分餾市場規模（依最終用戶分類）及複合年成長率（2025-2032）

市場概覽
醫院和診所
臨床研究實驗室
學術機構

血漿分餾市場規模（按地區）及複合年成長率（2025-2032）

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Grifols, SA（Spain）
Takeda Pharmaceutical Company Limited（Japan）
Octapharma AG（Switzerland）
Kedrion SpA（Italy）
Biotest AG（Germany）
LFB SA（France）
Sanquin Blood Supply Foundation（Netherlands）
China National Biotec Group Company Limited（China）
ADMA Biologics, Inc.（USA）
GC Biopharma Corp.（South Korea）
Hualan Biological Bacterin Inc.（China）
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
Shanghai RAAS Blood Products Co., Ltd.（China）

主要進展

Bio Products Laboratory Ltd (UK)
Green Cross Corporation (South Korea)
TianTan Biological Products Corporation Limited (China)
Emergent BioSolutions Inc. (USA)
Kamada Ltd. (Israel)

結論和建議

簡介目錄

Product Code: SQMIG35H2165

Global Plasma Fractionation Market size was valued at USD 33.43 billion in 2023 and is poised to grow from USD 36.2 billion in 2024 to USD 68.52 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global plasma fractionation market is poised for significant growth, primarily driven by an aging population that is increasingly susceptible to rare diseases requiring plasma-derived treatments. Plasma fractionation involves separating blood plasma to produce vital products such as immunoglobulins and factor VIII, which are critical in treating conditions like hemophilia and immunological deficiencies. The rising prevalence of these therapeutic applications, alongside a surge in plasma collection facilities, further propels market expansion. Additionally, government initiatives aimed at increasing awareness about plasma-derived products are contributing to market dynamics. However, the high cost associated with these plasma derivatives poses a challenge to growth, underscoring the need for strategies that enhance affordability and accessibility in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Fractionation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Fractionation Market Segments Analysis

Global Plasma Fractionation Market is segmented by Product, Application, End User and region. Based on Product, the market is segmented into Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors and Other Plasma Products. Based on Application, the market is segmented into Neurology, Immunology, Hematology, Critical care, Pulmonology, Hemato-Oncology, Rheumatology and Other Applications. Based on End User, the market is segmented into Hospitals and Clinics, Clinical Research Laboratories and Academic institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Plasma Fractionation Market

The increasing prevalence of diseases associated with immunodeficiency disorders and autoimmune conditions is a significant factor driving the expansion of the global plasma fractionation market. As healthcare professionals increasingly rely on immunoglobulins to treat these conditions, the demand for such products has surged. This rising demand not only propels growth in the market but also fosters innovation in the purification processes and manufacturing of plasma-derived therapeutic products. Consequently, this trend emphasizes the necessity for advancements in plasma fractionation technologies, further contributing to the development of effective treatments for patients suffering from these complex health issues.

Restraints in the Global Plasma Fractionation Market

The Global Plasma Fractionation market faces significant constraints stemming from the economic awareness of industry participants, which can lead to the establishment of barriers to entry in regions lacking support for economic growth. High costs associated with the plasma fractionation process, driven by sophisticated technology and stringent regulations, pose a challenge. These expenses create a barrier to market comprehension, particularly for smaller companies, hampering their potential for expansion. This situation is particularly pronounced in price-sensitive regions, where the financial burden can restrict participation and limit opportunities for development in the plasma fractionation sector.

Market Trends of the Global Plasma Fractionation Market

The global plasma fractionation market is witnessing significant growth driven by the surging demand for specialized plasma-derived products such as immunoglobulins and clotting factor concentrates. This trend is largely fueled by the rising prevalence of chronic and autoimmune diseases, prompting healthcare systems to seek more effective and targeted treatment solutions. Additionally, advancements in fractionation technologies and an expanding patient population are further propelling market expansion. As awareness of plasma-based therapies increases, stakeholders in this sector are investing in research and development to enhance product efficacy and safety, positioning the global plasma fractionation market for robust growth in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Plasma Fractionation Market Size by Product & CAGR (2025-2032)

Market Overview
Immunoglobulins
- Intravenous Immunoglobulins
- Subcutaneous Immunoglobulins
- Other Immunoglobulins
Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Von Willebrand Factor
- Prothrombin Complex Concentrate
- Fibrinogen Concentrates
- Factor XIII
- Other Coagulation Factor Concentrates
Albumin
Protease Inhibitors
Other Plasma Products

Global Plasma Fractionation Market Size by Application & CAGR (2025-2032)

Market Overview
Neurology
Immunology
Hematology
Critical care
Pulmonology
Hemato-Oncology
Rheumatology
Other Applications

Global Plasma Fractionation Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals and Clinics
Clinical Research Laboratories
Academic institutes

Global Plasma Fractionation Market Size & CAGR (2025-2032)

North America (Product, Application, End User)
- US
- Canada
Europe (Product, Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanquin Blood Supply Foundation (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China National Biotec Group Company Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GC Biopharma Corp. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hualan Biological Bacterin Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates

Key Developments

Bio Products Laboratory Ltd (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Green Cross Corporation (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TianTan Biological Products Corporation Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kamada Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments